Last reviewed · How we verify
LEO 29102 Plus Betamethasone Dipropionate
LEO 29102 Plus Betamethasone Dipropionate is a Small molecule drug developed by LEO Pharma. It is currently in Phase 2 development.
At a glance
| Generic name | LEO 29102 Plus Betamethasone Dipropionate |
|---|---|
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEO 29102 Plus Betamethasone Dipropionate CI brief — competitive landscape report
- LEO 29102 Plus Betamethasone Dipropionate updates RSS · CI watch RSS
- LEO Pharma portfolio CI
Frequently asked questions about LEO 29102 Plus Betamethasone Dipropionate
What is LEO 29102 Plus Betamethasone Dipropionate?
LEO 29102 Plus Betamethasone Dipropionate is a Small molecule drug developed by LEO Pharma.
Who makes LEO 29102 Plus Betamethasone Dipropionate?
LEO 29102 Plus Betamethasone Dipropionate is developed by LEO Pharma (see full LEO Pharma pipeline at /company/leo-pharma).
What development phase is LEO 29102 Plus Betamethasone Dipropionate in?
LEO 29102 Plus Betamethasone Dipropionate is in Phase 2.